Mont-Saint-Guibert, Belgium – 17 December 2021 – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 17, 2021 indicating that Tolefi SA and related persons have crossed together the statutory threshold of 20%, holding 18,65% of the voting rights of the company as of 8 December 2021.
Content of the Notification:
- Reason of the Notification:
Downward passive crossing of the 20% threshold
Downward passive crossing by persons acting in concert
- Notification by:
Persons acting in concert
- Persons subject to the notification requirement:
Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle
Serge Goblet
Isabelle Thoumyre
Jérôme Goblet
Jean-Daniel Goblet
- Transaction date
December 8, 2021
- Threshold that is crossed (in %)
20
- Denominator
24.961.981
- Notified details:
| A) Voting Rights | Previous notification | After the Transaction | |||
| #of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to the securities | Not linked to the securities | Linked to the securities | Not linked to the securities | |
| Tolefi SA | 4.591.402 | 4.591.402 | 18,39% | ||
| Serge Goblet | 56.180 | 56.180 | 0,23% | ||
| Isabelle Thoumyre | 7.300 | 7.300 | 0,03% | ||
| Jérôme Goblet | 250 | 250 | 0,00% | ||
| Jean-Daniel Goblet | 384 | 384 | 0,00% | ||
| TOTAL | 4.655.516 | 4.655.516 | 18,65% |
Tolefi SA is 100% controlled by Serge Goblet, Isabelle Thoumyre, Jérôme and Jean-Daniel Goblet.
Miscellaneous
- The Press Release may be consulted on the website of Celyad Oncology via this link.
The notification can be consulted on the website if Celyad Oncology via this link.
- Contact person(s):
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
